893428-66-5

Basic information

• Product Name: 2-Amino-4,6-difluorobenzamide
• Synonyms: 2-Amino-4,6-difluorobenzamide
• CAS NO: 893428-66-5
• Molecular Weight: 172.134
• Mol File: 893428-66-5.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 2-Amino-4,6-difluorobenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-4,6-difluorobenzamide(893428-66-5)
• EPA Substance Registry System: 2-Amino-4,6-difluorobenzamide(893428-66-5)

Safety Data

• Hazardous Substances Data: 893428-66-5(Hazardous Substances Data)

Usage

Chemical Structure

Benzene ring with two amino groups (-NH2) and two fluorine atoms (F) attached.

Application

Utilized in organic synthesis and pharmaceutical research.

Biological Activity

Acts as a building block for biologically active compounds.

Medicinal Chemistry

Important for drug development and discovery.

Biochemical Research

Used to study protein interactions and metabolic pathways.

Potential

Promising molecule for further scientific and medical investigation.

Upstream product

• 126674-93-9 4,6-difluoro-1H-indole-2,3-dione 
• 372-39-4 3,5-difluoroaniline 
• 940054-61-5 N-(3,5-difluorophenyl)-2-hydroxyiminoacetamide 
• 126674-77-9 2-amino-4,6-difluorobenzoic acid 
• 940054-62-6 2-amino-4,6-difluorobenzoic acid cyanomethyl ester 
• 190011-84-8 2-amino-4,6-difluorobenzonitrile 
• 207297-92-5 4-amino-2,6-difluorobenzonitrile 

Downstream Products

• 379228-58-7 5,7-difluoroquinazolin-4(3H)-one 
• 1246251-24-0 2-(2,6-dimethylpyridin-4-yl)-7-fluoro-5-(2-phenoxyethoxy)-3H-quinazolin-4-one 
• 1246251-23-9 2-(2,6-dimethylpyridin-4-yl)-7-methoxy-5-(2-phenoxyethoxy)quinazolin-4(3H)-one 
• 1246251-30-8 7-(2-(benzyloxy)ethoxy)-2-(2,6-dimethylpyridin-4-yl)-5-methoxyquinazolin-4(3H)-one 
• 940054-64-8 3-(2-amino-4,6-difluorobenzylamino)-pyrrolidine-2,5-dione 
• 1246251-22-8 2-(2,6-dimethylpyridin-4-yl)-5-methoxy-7-(2-phenoxyethoxy)quinazolin-4(3H)-one 
• 1610373-05-1 tert-butyl 3-((5-(5,7-difluoro-4-oxo-3,4-dihydroquinazolin-2-yl)-4'-(methylsulfinyl)-[1,1'-biphenyl]-2-yl)oxy)azetidine-1-carboxylate 
• 1610373-00-6 5,7-difluoro-2-(6-(4-(methylsulfonyl)phenyl)pyridin-2-yl)quinazolin-4(3H)-one 
• 1246250-80-5 2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-difluoroquinazolin-4(3H)-one 
• 1253731-70-2 5-(2-dimethylaminoethoxy)-2-(4-hydroxy-3,5-dimethylphenyl)-7-methoxy-3H-quinazolin-4-one 
• 1253731-73-5 2-(4-benzyloxy-3,5-dimethylphenyl)-5-(2-dimethylaminoethoxy)-7-methoxy-3H-quinazolin-4-one 
• 1253731-72-4 2-(4-benzyloxy-3,5-dimethylphenyl)-5-(2-dimethylaminoethoxy)-7-fluoro-3H-quinazolin-4-one 
• 1246250-74-7 5,7-difluoro-2-[4-(2-hydroxy-ethoxy)-3,5-dimethyl-phenyl]-3H-quinazolin-4-one 
• 1246251-06-8 7-[2-(benzyloxy)ethoxy]-5-methoxy-2-(pyridin-4-yl)quinazolin-4(3H)-one 

Relevant articles and documents

DIACYLGLYCEROL KINASE MODULATING COMPOUNDS

The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.

NOVEL ANTI-INFLAMMATORY AGENTS

Disclosed are methods of regulating interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring or synthetic quinazolone derivative. The invention provides novel synthetic quinazolone compounds, as well as pharmaceutical compositions comprising those compounds.

Pyrrolidine(thi)ones Substituted by Heterocyclic Substituents in The 3-Position

Pyrrolidine(thi)one compounds substituted by heterocyclic substituents in the 3-position, their preparation and use in pharmaceutical compositions, in particular as immunomodulators for treatment and/or inhibition of inflammatory and autoimmune diseases and haematological-oncological diseases.